A review of avelumab in locally advanced and metastatic bladder cancer

Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Urology 2019-01, Vol.11, p.1756287218823485-1756287218823485
Main Authors: Rao, Arpit, Patel, Manish R.
Format: Article
Language:English
Subjects:
Bladder cancer
Cancer therapies
FDA approval
Immunotherapy
Medical prognosis
Metastasis
Monoclonal antibodies
Review
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c458t-8e41970c7974a78c66b87a55bafc4c622a68b18a8776bdbd611a91792cfc923f3
cites cdi_FETCH-LOGICAL-c458t-8e41970c7974a78c66b87a55bafc4c622a68b18a8776bdbd611a91792cfc923f3
container_end_page 1756287218823485
container_issue
container_start_page 1756287218823485
container_title Therapeutic Advances in Urology
container_volume 11
creator Rao, Arpit
Patel, Manish R.
description Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer.
doi_str_mv 10.1177/1756287218823485
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a54bc26e3c2b4872934c2195ea499e02</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1756287218823485</sage_id><doaj_id>oai_doaj_org_article_a54bc26e3c2b4872934c2195ea499e02</doaj_id><sourcerecordid>2375712336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-8e41970c7974a78c66b87a55bafc4c622a68b18a8776bdbd611a91792cfc923f3</originalsourceid><addsrcrecordid>eNp1kUtv1DAQgCMEoqVw54QsceES8PtxQaoqCpUqcYGzNX5kycqJi51s1X-Ply0LrcTJ1sw3n8czXfea4PeEKPWBKCGpVpRoTRnX4kl3ug_1VGv89HhX9KR7UesWY8klpc-7E4ZVQ4Q57S7PUYm7Md6iPCDYxbRO4NA4o5Q9pHSHIOxg9jEgmAOa4gJ1gWX0yCUIIRbk99nysns2QKrx1f151n2__PTt4kt__fXz1cX5de-50EuvIydGYa-M4qC0l9JpBUI4GDz3rTeQ2hENWinpgguSEDBEGeoHbygb2Fl3dfCGDFt7U8YJyp3NMNrfgVw2FkprL0ULgjtPZWSeOt5mYBj3lBgRgRsTMW2ujwfXzeqmGHyclwLpgfRhZh5_2E3eWckEZ5g1wbt7Qck_11gXO43Vx5RgjnmtllJqsFLK7NG3j9BtXsvcRmUpU0IRyphsFD5QvuRaSxyOzRBs9wu3jxfeSt78-4ljwZ8NN6A_ABU28e-r_xX-AkFesVU</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2375712336</pqid></control><display><type>article</type><title>A review of avelumab in locally advanced and metastatic bladder cancer</title><source>Publicly Available Content Database</source><source>Sage Journals GOLD Open Access 2024</source><source>PubMed Central</source><creator>Rao, Arpit ; Patel, Manish R.</creator><creatorcontrib>Rao, Arpit ; Patel, Manish R.</creatorcontrib><description>Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer.</description><identifier>ISSN: 1756-2872</identifier><identifier>EISSN: 1756-2880</identifier><identifier>DOI: 10.1177/1756287218823485</identifier><identifier>PMID: 30728859</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Bladder cancer ; Cancer therapies ; FDA approval ; Immunotherapy ; Medical prognosis ; Metastasis ; Monoclonal antibodies ; Review ; Targeted cancer therapy</subject><ispartof>Therapeutic Advances in Urology, 2019-01, Vol.11, p.1756287218823485-1756287218823485</ispartof><rights>The Author(s), 2019</rights><rights>The Author(s), 2019. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://www.creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s), 2019 2019 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-8e41970c7974a78c66b87a55bafc4c622a68b18a8776bdbd611a91792cfc923f3</citedby><cites>FETCH-LOGICAL-c458t-8e41970c7974a78c66b87a55bafc4c622a68b18a8776bdbd611a91792cfc923f3</cites><orcidid>0000-0003-2752-945X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354303/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2375712336?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,723,776,780,788,881,21945,25731,27830,27899,27901,27902,36989,36990,44566,44921,45309,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30728859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rao, Arpit</creatorcontrib><creatorcontrib>Patel, Manish R.</creatorcontrib><title>A review of avelumab in locally advanced and metastatic bladder cancer</title><title>Therapeutic Advances in Urology</title><addtitle>Ther Adv Urol</addtitle><description>Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer.</description><subject>Bladder cancer</subject><subject>Cancer therapies</subject><subject>FDA approval</subject><subject>Immunotherapy</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Review</subject><subject>Targeted cancer therapy</subject><issn>1756-2872</issn><issn>1756-2880</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kUtv1DAQgCMEoqVw54QsceES8PtxQaoqCpUqcYGzNX5kycqJi51s1X-Ply0LrcTJ1sw3n8czXfea4PeEKPWBKCGpVpRoTRnX4kl3ug_1VGv89HhX9KR7UesWY8klpc-7E4ZVQ4Q57S7PUYm7Md6iPCDYxbRO4NA4o5Q9pHSHIOxg9jEgmAOa4gJ1gWX0yCUIIRbk99nysns2QKrx1f151n2__PTt4kt__fXz1cX5de-50EuvIydGYa-M4qC0l9JpBUI4GDz3rTeQ2hENWinpgguSEDBEGeoHbygb2Fl3dfCGDFt7U8YJyp3NMNrfgVw2FkprL0ULgjtPZWSeOt5mYBj3lBgRgRsTMW2ujwfXzeqmGHyclwLpgfRhZh5_2E3eWckEZ5g1wbt7Qck_11gXO43Vx5RgjnmtllJqsFLK7NG3j9BtXsvcRmUpU0IRyphsFD5QvuRaSxyOzRBs9wu3jxfeSt78-4ljwZ8NN6A_ABU28e-r_xX-AkFesVU</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Rao, Arpit</creator><creator>Patel, Manish R.</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2752-945X</orcidid></search><sort><creationdate>201901</creationdate><title>A review of avelumab in locally advanced and metastatic bladder cancer</title><author>Rao, Arpit ; Patel, Manish R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-8e41970c7974a78c66b87a55bafc4c622a68b18a8776bdbd611a91792cfc923f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bladder cancer</topic><topic>Cancer therapies</topic><topic>FDA approval</topic><topic>Immunotherapy</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Review</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rao, Arpit</creatorcontrib><creatorcontrib>Patel, Manish R.</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Therapeutic Advances in Urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rao, Arpit</au><au>Patel, Manish R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A review of avelumab in locally advanced and metastatic bladder cancer</atitle><jtitle>Therapeutic Advances in Urology</jtitle><addtitle>Ther Adv Urol</addtitle><date>2019-01</date><risdate>2019</risdate><volume>11</volume><spage>1756287218823485</spage><epage>1756287218823485</epage><pages>1756287218823485-1756287218823485</pages><issn>1756-2872</issn><eissn>1756-2880</eissn><abstract>Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>30728859</pmid><doi>10.1177/1756287218823485</doi><orcidid>https://orcid.org/0000-0003-2752-945X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1756-2872
ispartof Therapeutic Advances in Urology, 2019-01, Vol.11, p.1756287218823485-1756287218823485
issn 1756-2872
1756-2880
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a54bc26e3c2b4872934c2195ea499e02
source Publicly Available Content Database; Sage Journals GOLD Open Access 2024; PubMed Central
subjects Bladder cancer
Cancer therapies
FDA approval
Immunotherapy
Medical prognosis
Metastasis
Monoclonal antibodies
Review
Targeted cancer therapy
title A review of avelumab in locally advanced and metastatic bladder cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T07%3A03%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20review%20of%20avelumab%20in%20locally%20advanced%20and%20metastatic%20bladder%20cancer&rft.jtitle=Therapeutic%20Advances%20in%20Urology&rft.au=Rao,%20Arpit&rft.date=2019-01&rft.volume=11&rft.spage=1756287218823485&rft.epage=1756287218823485&rft.pages=1756287218823485-1756287218823485&rft.issn=1756-2872&rft.eissn=1756-2880&rft_id=info:doi/10.1177/1756287218823485&rft_dat=%3Cproquest_doaj_%3E2375712336%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c458t-8e41970c7974a78c66b87a55bafc4c622a68b18a8776bdbd611a91792cfc923f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2375712336&rft_id=info:pmid/30728859&rft_sage_id=10.1177_1756287218823485&rfr_iscdi=true